Sysmex (OTCMKTS:SSMXY) Sees Large Volume Increase – What’s Next?

Sysmex Corporation ADR (OTCMKTS:SSMXY) saw strong trading volume on Tuesday. Approximately 616,438 shares traded hands during trading, an increase of 188% from the average daily volume of 213,742 shares. The stock last traded at $12.30 and had previously closed at $12.44.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded Sysmex from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 18th. Two investment analysts have rated the stock with a Hold rating. According to data from MarketBeat, Sysmex has a consensus rating of “Hold”.

Sysmex Stock Down 1.5%

The business’s 50 day moving average is $11.94 and its 200 day moving average is $9.93. The company has a market capitalization of $7.36 billion, a price-to-earnings ratio of 28.81 and a beta of 1.18. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.53 and a current ratio of 3.40.

Sysmex (OTCMKTS:SSMXY) last posted its quarterly earnings results on Friday, August 7th. The company reported $0.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $0.02. The business had revenue of $825.85 million during the quarter, compared to analysts’ expectations of $741.67 million. Sysmex had a net margin of 7.62% and a return on equity of 8.01%. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. Sell-side analysts anticipate that Sysmex Corporation ADR will post 0.41 earnings per share for the current year.

Sysmex Company Profile

Sysmex Corporation is a Japan-based healthcare technology company that develops, manufactures and distributes clinical laboratory instruments, reagents and related information systems. Its products are used by hospitals, diagnostic laboratories and other healthcare providers to support the analysis of blood, urine and other biological samples.

The company is best known for its hematology analyzers, which help laboratories evaluate blood cells and identify conditions such as anemia and leukemia.